Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation
- 1Longeveron, INC
Abstract
Neuroinflammation is a principal driver of brain atrophy and cognitive decline in Alzheimers disease (AD). Here we show that laromestrocel, a mesenchymal stem cell therapy, inhibits progressive brain inflammation in subjects (n=49) with mild AD, with the strongest effect seen in core AD brain regions: the left hippocampus (25 million cells (M)x4 monthly dose group; p<0.001, N=11, and 100Mx4 group; p<0.001; N=10), the left temporal cortex (25Mx4 group; p=0.007; N=11) and left parietal cortex (25Mx4, week 26; p=0.042; N=10), and the medulla (25Mx4 group and 100Mx4; p=0.007; N=11 and N=10) after 39 weeks compared with placebo (N=9). Reduced neuroinflammation correlated with reduced brain atrophy (hippocampus: R=-0.326; p=0.040; N=40) and improvements in clinical scores, particularly cognitive function (hippocampus x MoCA: R=-0.401; p=0.011; N=40). Treated subjects also exhibited reduced neurogranin (25Mx4 group; p=0.023; N=11) in blood plasma, consistent with reduced synaptic loss. Finally, blood biomarker analysis supported a convergent multimodal mechanism of action implicating peripheral immune engagement. Together these results show that long-lasting anti-neuroinflammatory effects of laromestrocel mitigate AD brain inflammation and are associated with markedly reduced brain tissue destruction and improved clinical function.
Related
- Islet amyloid polypeptide exacerbates cognitive impairment, neuroinflammation, and hippocampal Aβ plaque deposition in Alzheimer’s disease mice by inhibiting the PI3K/Akt pathway
- Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
- Memory Self-Awareness Phenotypes are Associated with Alzheimers Disease Biomarker Burden and Clinical Progression in Amnestic Mild Cognitive Impairment
- Overexpression of hippocampal AdipoR1 ameliorates cognitive dysfunction in APP/PS1 mice through inhibiting NLRP3-Mediated neuronal pyroptosis
- Brain AT₁ Receptor Involvement in Cognitive Decline and Neuroinflammation in Streptozotocin-Treated Rats
BibTeX
@misc{rash2026laromestrocel,
title = {{Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation}},
author = {B. G. Rash and S. Levitina and J. Botbyl and C. Conklin and M. Ingalhalikar and J. M. Hare},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.16.26363132},
url = {https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation
AU - B. G. Rash
AU - S. Levitina
AU - J. Botbyl
AU - C. Conklin
AU - M. Ingalhalikar
AU - J. M. Hare
PY - 2026
DA - 2026/09/16
PB - medRxiv
DO - 10.64898/2026.09.16.26363132
UR - https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
AB - Neuroinflammation is a principal driver of brain atrophy and cognitive decline in Alzheimers disease (AD). Here we show that laromestrocel, a mesenchymal stem cell therapy, inhibits progressive brain inflammation in subjects (n=49) with mild AD, with the strongest effect seen in core AD brain regions: the left hippocampus (25 million cells (M)x4 monthly dose group; p<0.001, N=11, and 100Mx4 group; p<0.001; N=10), the left temporal cortex (25Mx4 group; p=0.007; N=11) and left parietal cortex (25Mx4, week 26; p=0.042; N=10), and the medulla (25Mx4 group and 100Mx4; p=0.007; N=11 and N=10) after 39 weeks compared with placebo (N=9). Reduced neuroinflammation correlated with reduced brain atrophy (hippocampus: R=-0.326; p=0.040; N=40) and improvements in clinical scores, particularly cognitive function (hippocampus x MoCA: R=-0.401; p=0.011; N=40). Treated subjects also exhibited reduced neurogranin (25Mx4 group; p=0.023; N=11) in blood plasma, consistent with reduced synaptic loss. Finally, blood biomarker analysis supported a convergent multimodal mechanism of action implicating peripheral immune engagement. Together these results show that long-lasting anti-neuroinflammatory effects of laromestrocel mitigate AD brain inflammation and are associated with markedly reduced brain tissue destruction and improved clinical function.
ER -